EMEA-001006-PIP03-16
Key facts
| Invented name |
|
| Active substance |
nintedanib
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0124/2017
|
| PIP number |
EMEA-001006-PIP03-16
|
| Pharmaceutical form(s) |
Capsule, soft
|
| Condition(s) / indication(s) |
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Boehringer Ingelheim International GmbH
Tel. +49 6132 778271 |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|